1. Seibold LK, Sherwood MB, Kahook MY. Wound Modulation After Filtration Surgery. Survey of Ophthalmology. 2012; 57: 530-550
  2. Shaarawy TM, Sherwood MB, Hitchings RA, et al (eds) Glaucoma, ed 1, vol. 1. Philadelphia, Saunders Elsevier,2009: 229-231
  3. Broadway DC, Grierson I, Sturmer J, et al. Reversal of topical antiglaucoma medication effects on the conjunctiva. Arch Ophthalmol. 1996; 114:262-267
  4. Breusegem C, Spielberg L, Van Ginderdeuren R, et al.Preoperative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial. Ophthalmology. 2010; 117:1324-1330
  5. Stamper RL et al. Hypotonous macupopathy after trabeculectomy with subconjunctival 5-Fuorouracil. Am J Ophthalmol 1992; 114:544-553
  6. Whiteside-Michel J et al. Initial 5-Fuorouracil trabeculectomy in young patients. Ophthamology 1992; 99:7-13
  7. Smith MF et al. Results of intraoperative 5-Fuorouracil or lower dose Mitomycin C admistration on initial trabeculectomy surgery. J Glaucoma 1997; 6:104-100
  8. Razeghinejad MR, Havens SJ, Katz LJ. Trabeculectomy bleb-associated infections. Survey of Ophthalmology. 2017; 62: 591-610
  9. Blindlish R et al. Efficacy and safety of mitomycin C in primary trabeculectomy: five year follow-up.  Ophthalmology 2002; 109:1336-1342
  10. WunDunn et al. A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy. Am. J. Ophthalmol 2002; 134: 521-528
  11. Greenfield DS, Liebmann JM, Jee J, Ritch R. Late-onset bleb leaks after glaucoma filtering surgery. Arch Ophthalmol.1998;116:443-447
  12. Jampel HD, Quigley HA, Kerrigan-Baumrind LA, et al. Risk factors for late-onset infection following glaucoma filtrationsurgery. Arch Ophthalmol. 2001; 119:1001-1008
  13. Song A, Scott IU, Flynn HW Jr, et al. Delayed-onset bleb-associated endophthalmitis: clinical features and visual acuity outcomes. Ophthalmology. 2002; 109:985-991
  14. Cillino S, Casuccio A, Di Pace F, Cagini C, Ferraro LL, Cillino G. Biodegradable collagen matrix implant versus mitomycin-C in trabeculectomy: five-year follow-up. BMC Ophthalmology (2016) 16-24
  15. Yuan F, Chen X, Yan X, Wang L.  Biodegradable 3D-Porous Collagen Matrix (Ologen) Compared with Mitomycin C for Treatment of Primary Open-Angle Glaucoma: Results at 5 Years. Journal of Ophthalmology 2015,
  16. He M, Wang W, Zhang X, Huang W. Ologen Implant versus Mitomycin C for Trabeculectomy: A Systematic Review and Meta-Analysis. PLoS ONE 2014; 9: e85782. doi:10.1371/journal.pone.0085782
  17. Ji Q, Qi B, Liu L, et al. Efficacy and safety of Ologen implant versus mitomycin C in primary trabeculectomy: a metanalysis of randomized clinical trials. J Glaucoma. 2015; 24: 88-94
4th Edition - November 2018